Adecatumumab: Phase II discontinued

Micromet discontinued enrollment of a Phase II trial evaluating adecatumumab alone or following FOLFOX chemotherapy in

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE